Proderm Technology® Delivery System is a versatile drug delivery platform which facilitates the topical delivery of pharmaceutical agents. Marketed in cream, lotion, and foam formulations, Proderm Technology® consists of a unique chemical structure that facilitates superior penetration of drug ingredients into the dermal layer with a cosmetically elegant feel. The intellectual property underlying the Transdermal System is patent protected under U.S. Patent 5,993,830.
Proderm Technology® is utilized in our NeoSalus®, Salvax®, Hydro®, and Tersi® brands.
TwinDerm® Delivery System
The TwinDerm® is a two-step topical delivery system that permits application of two drug products in sequence in one convenient, easy-to-use packet. The convenience of this delivery system facilitates patient compliance in combination therapies that would otherwise be more complicated to administer. The intellectual property underlying the TwinDerm® System is patent protected under the following U.S. Patents: 5,254,109; 5,417,674; and 5,562,642. Quinnova is currently conducting development work on a variety of topical products to utilize the Twin Derm® System.
Microcyn® Technology is a proprietary process involving a unique, patented electrochemical treatment of a saline solution. The result is a pH neutral solution of hypochlorous acid, and its sodium salt, hypochlorite. Hypochlorous acid is a natural product the human body produces in response to injury.
In 2011, Quinnova entered into agreements with Oculus Innovative Sciences to obtain marketing rights for several skin and wound care products utilizing Microcyn® Technology.